Traveler's Diarrhea in Nepal - Changes in Etiology and Antimicrobial Resistance.
We conducted a comprehensive investigation to update our knowledge of traveler's diarrhea (TD) etiology and antimicrobial resistance (AMR) in Nepal. A case-control study of TD etiology was conducted at the CIWEC Clinic Travel Medicine Center in Kathmandu from 2012-2014. Stool samples were tested by microscopy, culture and molecular techniques for identification of bacterial, viral, and parasitic enteric pathogens, and AMR. We analyzed patient demographic data, pre-treatment information, and clinical outcomes. We enrolled 433 TD cases and 209 non-diarrhea controls. At least one of enteric pathogens were identified among 82% of cases and 44% of controls (p<0.001). Multiple pathogens were observed among 35% of cases and 10% of controls. The most common pathogens significantly identified among cases in comparison to controls were Campylobacter (20%), norovirus (17%), Enterotoxigenic E. coli (ETEC) (12%), rotavirus (9%) and Shigella (8%) (p< 0.001). We noted Campylobacter, Shigella, and ETEC resistance to azithromycin at 8%, 39% and 22%; and to ciprofloxacin (CIP) at 97%, 78% and 23%, respectively. Among travelers to Nepal with TD, viral pathogens were commonly found and Norovirus was the second most common pathogen after campylobacter. We noted increased AMR to fluoroquinolones (FQs) and azithromycin (AZM). There is heightened concern for AZM treatment failures, though this continues to remain the drug of choice for TD treatment in our setting where FQs should not be used.